Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2003-12-31
2009-10-27
Goldberg, Jeanine A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S007100, C536S023100, C536S024300, C530S350000
Reexamination Certificate
active
07608393
ABSTRACT:
A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.
REFERENCES:
patent: WO 9001069 (1990-02-01), None
patent: WO 98/37419 (1998-08-01), None
patent: WO 01/80712 (2001-11-01), None
patent: WO 2004/060135 (2004-07-01), None
Levy et al. Diabetes Care, vol. 27, No. 4, pp. 925-930, Apr. 2004.
N England J. Med, vol. 349, pp. 60-72, 2003.
Levy (Diabetes Care, vol. 27, No. 11, pp. 2767, Nov. 2004).
Levy (Pharmacology & Therapeutics, vol. 112, pp. 501-512, 2006).
Bublin, et al, Eur Heart J. 2003; 24:2099-2107.
De Bacquer, et al, Athcrosclerosis 2001; 157:161-1666.
Hong, et al, Hum Hered 1997; 47:283-7.
Hope Study Investigators NE J. Med 2000;342:154-160.
Lind, et al, Angiology 2003; 54:401-410.
Nishikawa, et al, Nature 2000; 404:787-790.
Ohgami, et al, J Diabetes Complic 2002; 16:56-59.
Stamler, et al, Diabetes Care 1993; 16: 434-444.
Steinberg D, (1997) Low density lipoprotein oxidation and its pathobiological significance.: J Biol Chem; 272-20963-6.
Williams, et al, (1992) “Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis.” Atherosclerosis; 94:153-159.
Brown, et al, “Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.” NE J Med 2001; 345: 1538-92.
Gissi, Lancet 1999; 354:4477-55.
Hodis, et al, Circulation 2002; 106:1453-59.
Jiang, et al, J Biol Chem 202; 277:31850-6.
Levy, et al, J Am Coll Card 2002; 40: 1984-90.
Marchioli, et al, Lipids; 2001: 36 Suppl: S53-63.
Melamed-Frank, et al, Blood 2001; 98: 3693-98.
Steinberg, et al, Circulation 2002; 105: 2107-2111.
UK Prospective Study Group Diab Care 1998; 21: 1271-1277.
Waters, et al, JAMA 2002; 288: 2342-40.
Witztum, et al, Trends Cardio Med 2001; 11:93-102.
Barany, PCR Methods and Applic., 1:5 (1991).
Barany, Proc. Natl Acad. Sci., 88: 189 (1991).
Brown, et al, N Eng J Med 2001; 345: 1583-1592.
Fahy, et al, “Self-sustained sequence replication (3SR): an isothermal transcription- based amplification system alternative to PCR.” PCR Meth. Appl., 1:25-33 (1991).
Guatelli, et al, Proc. Natl Acad. Sci., 87:1874-1878 (1990).
Mullis, PCR Methods Applic. 1:1 (1991).
The Heart Outcomes Prevention Evaluation Study Investigators N Eng J Med 2000; 342: 154-160.
Wu and Wallacc, Genomics 4: 560 (1989).
Barlow and Lehrach, Trends Genet., 3:167 (1987).
Conner, et al, Proc. Natl Acad. Sci. 80: 278-282 (1983).
Farr, et al, Proc. Natl. Acad. Sci. 85: 1629-1633 (1988).
Gogos, et al, “Detection of single base mismatches of thymine and cytosine residues by potassium permanganate and hydroxylamine in the presence of tetralkylammonium salts.” Nucl. Acids Res., 18: 6807-6817 (1990).
Kwok, et al, Nucl. Acids Res., 18:999 (1990).
Lyons, et al, Science 249: 655-659 (1990).
Perlman and Butow, Science 246: 1106 (1989).
Urdea, et al, Gene 61: 253-264 (1987).
Vogelstein, et al, N Eng. J. Med. 319: 525-532 (1988).
Abrams, et al, Genomics 7: 463-475 (1990).
Borrensen, et al, Proc. Natl Acad. Sci. USA 88: 8405 (1991).
Hayashi, Sekya and collegues PCR Meth. Appl. 1: 34-38 (1991).
Lerman and Silverstein, Meth Enzymol, 155: 482-501 (1987).
Liu and Sommer, PCR Methods Applic 4: 97 (1994).
Orita, et al, Genomics 5: 874-879 (1989).
Scholtz, et al, Hum. Mol. Genet. 2: 2155 (1993).
Sheffield, et al, Proc Natl. Acad. Sci. 86: 232-236 (1989).
Smith, et al, Genomics 3:217-223 (1988).
Wartell, et al, Nucl. Acids Res., 18: 2699-2701 (1990).
Campo, et al, Cardiovasc Drug Rev 1997; 15: 157-173.
Kita, et al, PNAS USA 1987; 84: 7725.
Mak, et al, Pharma Res. 2002; 45: 27-33.
Meng, et al, Bioorg Med Chem Ltrs 2002; 12: 2545-48.
Sagach, et al, Pharma Res 202; 45: 435-439.
Yoshida, et al, Altheroscler 2002; 162: 111-117.
Blum et al.; Journal of the American College of Cardiology vol. 49 No. 1, 2007.
Milman et al.; Vitamin E Supplementation Reduces Cardiovasuclar Events in a Subgroup of Middle-Aged Individual With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype; Journal of the Amercia Heart Association Nov. 21, 2007.
Supplementary European Search Report Issued in EP 04 79 9315; Jun. 26, 2009.
Office Action Issued in CN 2003801180094.8; Jun. 5, 2009.
Cohen Mark S.
Goldberg Jeanine A
Pearl Cohen Zedek Latzer LLP
Rappaport Family Institute for Research in the Medical Sciences
LandOfFree
Methods of predicting a benefit of antioxidant therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of predicting a benefit of antioxidant therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of predicting a benefit of antioxidant therapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103042